Zhi Tong Cai Jing·2025-08-29 02:44Core Insights - Rongchang Biopharma (09995) shares increased by approximately 9%, reaching HKD 95.95 with a trading volume of HKD 383 million [1] Financial Performance - For the first half of the year, the company reported revenue of CNY 1.09 billion, representing a year-on-year growth of 48% [1] - The net loss attributable to shareholders was CNY 450 million, which is a reduction in loss by CNY 330 million compared to the previous year [1] Product Performance - The revenue growth is primarily driven by increased sales of its core products, Tai Taisip and Vidi Sima, both of which were included in the medical insurance directory in 2021 [1] - The approval of Tai Taisip for gMG has been granted, with expectations for pSS and IgAN to submit for market approval in the second half of 2025 [1] - Vidi Sima has received approval for treating second-line HER2-positive breast cancer with liver metastasis, and applications for additional indications are underway, which is expected to accelerate commercialization [1]